Navigation Links
Results from 8 late-breaking clinical trials presented at Heart Failure 2009
Date:5/30/2009

Results and updates from eight studies were presented during a late-breaking trials session at Heart Failure 2009. Reviewing them at a press conference, Professor John McMurray, President of the Heart Failure Association, described the trials' objectives and main implications.

A multicentre study of a new inotropic drug (which increases the contraction and pumping of the heart), CK-1827452, found that it increases systolic function in stable heart failure patients and was well tolerated in a proof of concept study. CK-1827452 is a new drug in a class known as Selective Cardiac Myosin Activators. Bigger trials are now needed to assess safety and effect on clinically meaningful endpoints.

Pre-RELAX-AHF is another proof of concept study with an interesting new vasodilator drug (relaxin), a hormone produced by the ovaries and placenta during pregnancy which causes expansion of the cervix and uterus. Because relaxin also relaxes arteries and veins, it reduces the resistance to bloodflow in these vessels - and hence the work the heart has to do to pump blood through them. Results of this trial are encouraging and showed that relaxin given for 48 hours produce rapid and sustained improvement in breathlessness and other heart failure symptoms, with a favourable impact on clinical outcomes at 60 days. Again, bigger trials are now needed to assess safety and effect on clinically meaningful endpoints.

CHANCE (Congestive Heart failure: A multidisciplinary Non-pharmacological approach for Changing in rE-hospitalisation and prognosis) is an important study from Russia looking at whether post-discharge non-pharmacological interventions by nurses and other health professionals could reduce the risk of hospital readmission. The study found that an approach of patient education and active follow-up (added to optimal medical care) decreased morbidity and mortality. This reinforces the findings of previous studies in other countries and suggests that organised multidisciplinary care is beneficial for patients with heart failure in a variety of healthcare systems.

B-convinced is a multicentre French study designed to assess the effect of temporarily discontinuing beta-blockers in patients whose worsening heart failure leads to hospital admission. This reflects a frequent clinical dilemma but results showed that during acute heart failure beta-blocker therapy should not be withdrawn.

CHAT (Chronic Heart failure Assistance by Telephone) is a fascinating study looking at whether telephone intervention (with advice about symptoms, treatment, etc) might be helpful in reducing the risk of major heart failure events (hospital admissions/death) in patients living in rural areas (where organised multidisciplinary care is not available). Results from this randomised trial performed in Australia suggest that telephone support can significantly reduce mortality and hospitalisation rate in a rural and remote cohort.

CIBIS-ELD (Cardiac Insufficiency Bisoprolol Study in Elderly) was designed to assess and compare the dose of two proven beta-blockers in elderly patients with heart failure (the elderly are often "underdosed" and there is always debate about whether one drug might be better tolerated than another). This study showed that it is indeed hard to achieve the target dose in elder patients, and that there was no difference in tolerability between the two (bisoprolol and carvedilol).

Ex-DHF is an interesting study which looked at a neglected type of heart failure, diastolic HF (or HF with preserved ejection fraction). There are no proven treatments for this type of heart failure, and this study tested the value of exercise training. The results showed that this intervention improved exercise capacity, made patients feel better and, importantly, seemed to improve the abnormalities in the structure and function of the heart in these patients.

SIGNAL-HF studied the very topical and important question of whether use of the biomarker NT-pro BNP as a guide to pharmacological treatment in primary care would lead to an improvement in patient outcomes. It didn't and this will be a controversial conclusion alongside a number of conflicting and unconvincing recent findings in this area.


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... Ca (PRWEB) , ... August 18, 2017 , ... ... quality liquid handling handheld devices. Through an educational webinar, they will present the ... users a chance to learn how easy you can automate everyday pipetting tasks. ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... ... , ... “Emotions are sacred, valid, honored, encouraged. This is the memo we ... Mindful. To help change the mindset of parents and educators from punitive to positive ... Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in less ...
(Date:8/18/2017)... ... , ... Alcovit, a lime-flavored beverage that rids the body of toxins linked ... now available through Jet.com. , After 25 years of development, the company released ... to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: